These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9175303)

  • 1. Orthoclone OKT3 for graft failure after allogeneic bone marrow transplantation: a case report.
    Yen CC; Chen PM; Chiou TJ; Hsieh RK
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Feb; 59(2):126-31. PubMed ID: 9175303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
    Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation.
    Liedtke W; Quabeck K; Beelen DW; Straeten V; Schaefer UW
    J Neurol Sci; 1994 Aug; 125(1):110-1. PubMed ID: 7964881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophageal graft versus host disease.
    Sodhi SS; Srinivasan R; Thomas RM
    Gastrointest Endosc; 2000 Aug; 52(2):235. PubMed ID: 10922099
    [No Abstract]   [Full Text] [Related]  

  • 6. Phimosis as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Kami M; Kanda Y; Sasaki M; Takeda N; Tanaka Y; Saito T; Ogawa S; Honda H; Chiba S; Mitani K; Hirai H; Yazaki Y
    Bone Marrow Transplant; 1998 Apr; 21(7):721-3. PubMed ID: 9578313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia.
    Dilek I; Demirer T; Ustün C; Arat M; Koç H; Beksaç M; Erdi H; Anadolu R; Ozcan M; Ilhan O; Akan H
    Bone Marrow Transplant; 1998 Jun; 21(11):1159-61. PubMed ID: 9645582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of a patient with graft versus host reaction following allogenic bone marrow transplantation with the monoclonal antibody OKT3 (Orthoclone OKT3)].
    Jung G; Holler E; Kolb HJ; Wilmanns W
    Internist (Berl); 1989 Jun; 30(6):386-8. PubMed ID: 2503460
    [No Abstract]   [Full Text] [Related]  

  • 11. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP).
    Gerber M; Gmeinhart B; Volc-Platzer B; Kalhs P; Greinix H; Knobler R
    Bone Marrow Transplant; 1997 Mar; 19(5):517-9. PubMed ID: 9052923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.
    Owsianowski M; Gollnick H; Siegert W; Schwerdtfeger R; Orfanos CE
    Bone Marrow Transplant; 1994 Nov; 14(5):845-8. PubMed ID: 7889018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation.
    Browett PJ; Nelson J; Tiwari S; Van de Water NS; May S; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):641-4. PubMed ID: 7858542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
    N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-mediated T-cell depletion of bone marrow: comparison of T10B9.1A-31 and Muromonab-Orthoclone OKT3.
    Keever-Taylor CA; Craig A; Molter M; Fu P; Loebel A; Skonecki J; Zeng H; Giesen B
    Cytotherapy; 2001; 3(6):467-81. PubMed ID: 11953031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.